- Lilly and NVIDIA have partnered to establish an AI co-innovation lab dedicated to addressing drug discovery challenges. NVIDIA is also collaborating with Thermo Fisher to create autonomous lab infrastructure for scalable scientific discovery.
- The expansion of NVIDIA BioNeMo includes new open models, data processing libraries, and recipes to enhance biological foundation model training and deployment in drug discovery.
- The collaboration between Lilly and NVIDIA aims to revolutionize drug discovery by integrating accelerated computing and AI with Lilly’s drug development expertise. Thermo Fisher is also teaming up with NVIDIA to build autonomous lab infrastructure for scientific discovery.
- The NVIDIA-powered AI drug discovery ecosystem is growing, with companies like Basecamp Research, Boltz PBC, and Chai Discovery utilizing BioNeMo for scaling model training and development.
- AI scientist companies are leveraging NVIDIA NeMo framework to build domain-specific agents for science, accelerating scientific discovery with tools like Kosmos, developed by Edison Scientific, and OwkinZero, a frontier biology model.
- NVIDIA is working with robotics and lab automation companies to introduce simulation and physical AI technologies, bridging the gap between in-silico experimentation and real-world validation in drug discovery and scientific research.
Read more at Nvidia: NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery